These statements have not been evaluated by the FDA
Now, scientists are exploring whether those powerful effects could translate into a treatment for binge eating disorder, the most common eating disorder in the United States
Its true appetite-suppressing power unlocks incrementally as the concentration of the medication builds safely in your bloodstream over successive weeks
The FDA has lately expressed concerns over compounded semaglutide formulations and the risk of gastrointestinal complications, including ileus, underscoring the need of appropriate prescribing and monitoring practices (Lambson et al
Reduced appetite is also expected, but too little appetite can become a problem if it leads to under-eating
(25% of body weight), compared to 1.5% on placebo, according to data not controlled for type 1 error